Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The Validation set of the genomic nodal index (GNI) in 2014

ABSTRACT: The Validation set of the genomic nodal index (GNI) in 2014

PROVIDER: PRJNA980140 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

The Validation set of the genomic nodal index (GNI) in 2014

Project description:The aim of this study was to construct a prediction model for axillary lymph node metastasis (ALNM) using a DNA microarray assay for gene expression in breast tumor tissues. Luminal A breast cancers, diagnosed by PAM50 testing, were analyzed, and a prediction model (genomic nodal index (GNI)) consisting of 292 probe sets for ALNM was constructed in a training set of patients (n=388), and was validated in the first (n=59) and the second (n=103) validation sets. AUCs of ROC were 0.820, 0.717, and 0.749 in the training, first, and second validation sets, respectively. GNI was most significantly associated with ALNM, independently of the other conventional clinicopathological parameters in all cohorts. It is suggested that GNI can be used to identify the patients with a low risk for ALNM so that sentinel lymph node biopsy can be spared safely. This DATA set: J03 contains 120 (n+ 60, n- 60) samples of the above first and second validation sets from Japan (OUH_1,2). A long time passed, and now it is unclear how these 120 cases were distributed among the first and second validation sets. *Note: This old data has been updated multiple times by others. Then, there are some differences from the original 2014 paper and unclear points still remain. Therefore, do not use it for formal analysis aimed at public insurance coverage etc. This is for research purposes only. Please cite this paper when writing a new paper. PMID: 25016059 DOI: 10.1016/j.canlet.2014.07.003

2023-06-09 | GSE234114 | GEO

Endocrine Sensitivity Index Validation Dataset

Project description:Validation dataset of 298 ER-positive patients treated with tamoxifen for 5 years. All patients in this dataset have ER+ breast cancer and were uniformly treated with tamoxifen for 5 years. The objective of the study was to correlate levels of genomic markers to outcomes (relapse free survival) in this cohort of uniformly treated patients.

2010-08-13 | GSE17705 | GEO

Endocrine Sensitivity Index Validation Dataset

2010-08-13 | E-GEOD-17705 | biostudies-arrayexpress

High-frequency recurrence index for predicting multiple recurrences in non-muscle-invasive bladder cancer (Validation cohort)

Project description:Non-muscle invasive bladder cancer (NMIBC) has a recurrence rate of more than 50% after transurethral resection (TUR) and Calmette-Guérin (BCG) treatment. This study aimed to develop a high-frequency recurrence index (HfRI) to predict multiple recurrences in NMIBC patients and guide personalized treatment strategies. In this study, we analyzed transcriptome data (Discovery cohort) of 45 high-risk NMIBC patients who received intravesical BCG treatment, including patients with >=2 recurrences, to identify genes significantly associated with high-frequency recurrence and construct a signature. In addition, we validated the predictive performance using transcriptome data of 94 patients (Validation cohort).

2026-02-07 | GSE294705 | GEO

Development and Validation of a Disability Severity Index for Charcot-Marie-Tooth Disease (CMT) - INC 6604

Project description:Development and Validation of a Disability Severity Index for Charcot-Marie-Tooth Disease (CMT) - INC 6604

| PRJNA374388 | ENA

High-frequency recurrence index for predicting multiple recurrences in non-muscle-invasive bladder cancer (Validation cohort)

Project description:High-frequency recurrence index for predicting multiple recurrences in non-muscle-invasive bladder cancer (Validation cohort)

| PRJNA1251344 | ENA

Normalized expression (validation set) - samples

Project description:Normalized expression data; validation set

| EGAD00010000211 | EGA

Orientia tsutsugamushi strain:Wuj/2014 | isolate:Wuj/2014

Project description:Orientia tsutsugamushi strain:Wuj/2014 | isolate:Wuj/2014 Genome sequencing

| PRJNA563989 | ENA

Benchmarking dataset for measurement and removal of index hopping artifacts in multiplexed droplet-based single-cell RNA-seq data

Project description:Sample index hopping refers to the incorrect sample assignment of a demultiplexed sequencing read in a library pool. To enable benchmarking of methods for measurement of index hopping rate and removal of its artifacts in single-cell RNA-seq data, we developed a validation dataset consisting of a multiplexed library of two samples, in which the true sample of origin of most reads are known. The reads with known sample of origin provide the ground truth for measuring the performance of index hopping correcting methods.

2020-05-09 | GSE149087 | GEO

High-dose oncogenic PIK3CA drives constitutive cellular stemness through increased NODAL/TGFb signaling

Project description:Oncogenic PIK3CA mutations activate phosphoinositide 3-kinase (PI3K) and are among the commonest somatic mutations in cancer and mosaic, developmental overgrowth disorders. We recently demonstrated that the ‘hotspot’ variant PIK3CAH1047R exerts striking allele dose-dependent effects on stemness in human induced pluripotent stem cells (iPSCs), and moreover demonstrated multiple oncogenic PIK3CA copies in a substantial subset of human cancers. To identify the molecular mechanism underpinning PIK3CAH1047R allele dose-dependent stemness, we profiled isogenic wild-type, PIK3CAWT/H1047R and PIK3CAH1047R/H1047R iPSCs by high-depth transcriptomics, proteomics and reverse-phase protein arrays (RPPA). PIK3CAH1047R/H1047R iPSCs exhibited altered expression of 5644 genes and 248 proteins, whereas heterozygous hPSCs showed 492 and 54 differentially-expressed genes and proteins, respectively, confirming a nearly deterministic phenotypic effect of homozygosity for PIK3CAH1047R. Pathway and network-based analyses predicted a strong association between self-sustained TGFb/NODAL signaling and the ‘locked’ stemness phenotype induced by homozygosity for PIK3CAH1047R. This stemness gene signature was maintained without exogenous NODAL in PIK3CAH1047R/H1047R iPSCs and was reversed by pharmacological inhibition of TGFb/NODAL signaling but not by PIK3CA-specific inhibition. Analysis of PIK3CA-associated human breast cancers revealed increased expression of the stemness markers NODAL and POU5F1 as a function of disease stage and PIK3CAH1047R allele dosage. Together with emerging realization of the link between NODAL re-expression and aggressive cancer behavior, our data suggest that TGFb/NODAL inhibitors warrant testing in advanced breast tumors with multiple oncogenic PIK3CA copies.

2021-03-03 | PXD014719 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data